Journal ArticleDOI
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
Joseph Keane,Sharon K. Gershon,Robert P. Wise,Elizabeth Mirabile-Levens,John Kasznica,William D. Schwieterman,Jeffrey Siegel,M. Miles Braun +7 more
Reads0
Chats0
TLDR
Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis but there is no direct evidence of a protective role of TNF- α in patients with tuberculosis.Abstract:
Background Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis. Approximately 147,000 patients throughout the world have received infliximab. Excess TNF-α in association with tuberculosis may cause weight loss and night sweats, yet in animal models it has a protective role in the host response to tuberculosis. There is no direct evidence of a protective role of TNF-α in patients with tuberculosis. Methods We analyzed all reports of tuberculosis after infliximab therapy that had been received as of May 29, 2001, through the MedWatch spontaneous reporting system of the Food and Drug Administration. Results There were 70 reported cases of tuberculosis after treatment with infliximab for a median of 12 weeks. In 48 patients, tuberculosis developed after three or fewer infusions. Forty of the patients had extrapulmonary disease (17 had disseminated disease, 11 lymph-node disease, 4 peritoneal disease, 2 pleural dis...read more
Citations
More filters
Journal ArticleDOI
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
David E. Griffith,Timothy R. Aksamit,Barbara A. Brown-Elliott,Antonino Catanzaro,Charles L. Daley,Fred M. Gordin,Steven M. Holland,Robert Horsburgh,Gwen A. Huitt,Michael F. Iademarco,Michael D. Iseman,Kenneth N. Olivier,Stephen J. Ruoss,C. Fordham von Reyn,Richard J. Wallace,Kevin L. Winthrop +15 more
TL;DR: Diagnostic Criteria of Nontuberculous Mycobacterial Lung Disease Key Laboratory Features of N TM Health Careand Hygiene-associated Disease Prevention Prophylaxis and Treatment of NTM Disease Introduction Methods.
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
The pathophysiology and treatment of sepsis.
TL;DR: This review examines evolving concepts of sepsis and discusses new and potential therapies, including therapy with activated protein C, stringent control of blood glucose, and early goal-directed therapy to treat cellular oxygen deficit.
Journal ArticleDOI
Points of control in inflammation
TL;DR: The non-inflammatory state does not arise passively from an absence of inflammatory stimuli; rather, maintenance of health requires the positive actions of specific gene products to suppress reactions to potentially inflammatory stimuli that do not warrant a full response.
Journal ArticleDOI
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G. Feagan,Paul Rutgeerts,Bruce E. Sands,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,William J. Sandborn,Gert Van Assche,Jeffrey Axler,Hyo-Jong Kim,Silvio Danese,I. Fox,Catherine Milch,Serap Sankoh,Tim Wyant,Jingcan Xu,Asit Parikh +16 more
TL;DR: Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.
References
More filters
Journal ArticleDOI
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Peter E. Lipsky,D. van der Heijde,E W St Clair,Daniel E. Furst,F. C. Breedveld,J. R. Kalden,Josef S. Smolen,M Weisman,Paul Emery,Marc Feldmann,Gregory Harriman,Ravinder Nath Maini +11 more
TL;DR: In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotRexate provided clinical benefit and halted the progression of joint damage.
Journal ArticleDOI
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Ravinder N. Maini,E W St Clair,F. C. Breedveld,Daniel E. Furst,Joachim R. Kalden,Michael H. Weisman,Josef S. Smolen,Paul Emery,G Harriman,Marc Feldmann,Peter E. Lipsky +10 more
TL;DR: Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group.
Journal ArticleDOI
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Ernest Choy,Gabriel S. Panayi +1 more
TL;DR: Current slow-acting antirheumatic drugs have limited efficacy and many side effects and do not improve the long-term prognosis of rheumatoid arthritis.
Journal ArticleDOI
Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in mice
JoAnne L. Flynn,Marsha M. Goldstein,John Chan,Karla J. Triebold,Klaus Pfeffer,Charles J. Lowenstein,Robert Schrelber,Tak W. Mak,Barry R. Bloom +8 more
TL;DR: The data from both models established that TNF alpha and the 55 kDa TNF receptor are essential for protection against tuberculosis in mice, and for reactive nitrogen production by macrophages early in infection.
Journal ArticleDOI
The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
TL;DR: It is proposed that TNF released from macrophages in the microenvironment of developing granulomas is involved in a process of autoamplification: acting in an autocrine or paracrine way, it enhances its own synthesis and release, thus favoring further macrophage accumulation and differentiation leading to bacterial elimination.